Fecal Transplants May Offer Lifeline for Deadly Post-Transplant Complication

After allogeneic stem cell transplantation, a patient's own immune system becomes its worst enemy. Donor immune cells can attack the recipient's gut, skin, and liver in a condition called acute graft-versus-host disease, or aGVHD, and when the gastrointestinal tract is involved the mortality rate climbs as high as 55%. Standard corticosteroids fail in a large proportion of patients, and second-line drugs carry their own risks. A new meta-analysis published in Frontiers in Microbiology by Zhang, Lin, and colleagues synthesized data from six studies and 262 patients to ask whether fecal microbiota transplantation (FMT) could change the picture.

FMT Nearly Triples Response Rates for Gut GVHD Within 30 Days

The headline number is striking. Patients who received FMT were roughly eight times more likely to achieve a complete response in gastrointestinal aGVHD than those on conventional regimens, both at 14 days (OR = 8.54, 95% CI = 2.49 to 29.29, p = 0.0007) and at 30 days (OR = 8.44, 95% CI = 2.98 to 23.96, p < 0.0001). Complete response was defined as at least a 500 mL reduction in mean daily stool volume within three days, or full resolution of symptoms. Even when partial responses were included, FMT still outperformed controls at 14 days (OR = 4.66, 95% CI = 1.73 to 12.55, p = 0.002). Earlier work on FMT's role in restoring microbiota composition in GVHD had flagged this potential, but the pooled signal here is considerably stronger than any single-center result could deliver.

Gastrointestinal GVHD Stakes: 35 to 50 Percent of Transplant Patients Are at Risk

Acute GVHD affects 35 to 50 percent of hematopoietic stem cell transplant recipients, and gastrointestinal involvement is the most common and most dangerous presentation. The mechanism involves a collapse of the gut microbiome during pre-conditioning: radiotherapy and aggressive antibiotic regimens wipe out beneficial species like Bacteroides, Lactobacillus, and Bifidobacterium while opportunistic pathogens including Enterococcus and Clostridioides difficile fill the vacuum. That dysbiosis damages the intestinal mucosal barrier, floods the bloodstream with pathogen-associated molecular patterns, and fuels the inflammatory cascade that drives aGVHD. As a severe complication of stem cell transplantation, aGVHD represents one of the clearest unsolved problems in transplant medicine: about half of patients do not respond to first-line methylprednisolone, and no universally accepted second-line standard exists. FMT's appeal is conceptually direct: if dysbiosis drives the disease, restoring a healthy microbial ecosystem might interrupt it.

How the Meta-Analysis Pooled Evidence Across Six Countries

Pooling small studies through meta-analysis can substantially increase statistical power when no single trial is large enough to be conclusive on its own, and that is exactly the situation here. Zhang and colleagues searched PubMed, Embase, the Cochrane Library, and Web of Science through October 2025, ultimately including three randomized controlled trials and three cohort studies. Four studies were conducted in China, one in the United States, and one in Russia. FMT was delivered either as oral capsules or via nasoduodenal, nasojejunal, or nasogastric tube infusions. Control regimens varied and included corticosteroids with or without immunosuppressants, placebo, or blank control. Study quality was rated moderate to high, and a sensitivity analysis, in which each study was excluded in turn, confirmed the findings held up. The team also tracked gut microbiota changes and found FMT significantly increased the abundance of Bacteroides (SMD = 1.59, p = 0.03) and Bifidobacterium (SMD = 1.01, p = 0.0009), the two genera most depleted during pre-conditioning.

Prevention Results Are Mixed, and Donor Source Matters

The treatment signal is compelling, but the prevention picture is more complicated. Overall, FMT did not significantly reduce aGVHD incidence compared to conventional regimens (OR = 1.30, p = 0.84). A subgroup analysis by donor source revealed a meaningful divide: allogeneic FMT, meaning stool from a third-party donor, was actually associated with a higher risk of aGVHD compared to controls (OR = 5.07, 95% CI = 1.06 to 24.32, p = 0.04). Autologous FMT, where the patient's own pre-transplant stool is reinfused, showed no significant difference in aGVHD incidence (OR = 0.39, p = 0.06), though the trend was in a protective direction. This distinction matters clinically. It suggests that when using FMT to prevent aGVHD, the source of the transplanted microbiome may be as important as the intervention itself. On safety, there was no significant difference between FMT and control groups in rates of bacteremia (p = 0.05) or sepsis (p = 0.13), which is reassuring given that immunocompromised patients face elevated infection risk from any gut-directed intervention.

Open Questions About Long-Term Outcomes and Optimal Protocols

Several important limitations temper the enthusiasm. The combined sample of 262 patients is small, and four of the six studies come from China, raising questions about geographic and disease-spectrum generalizability. Most studies focused on patients with acute myeloid leukemia or acute lymphoblastic leukemia, leaving other transplant indications underrepresented. Long-term outcomes and dynamic microbiota data were largely absent, so it is not yet clear whether the early response gains translate into durable remissions or improved survival. Conditioning regimens and graft sources were inconsistently reported across studies, making direct comparisons difficult.

Ongoing randomized trials are now investigating optimized FMT protocols for stem cell transplant patients, including work on donor selection and dosing schedules. The authors also note that a phase I trial using oral encapsulated FMT for treatment-naive lower GI aGVHD found early clinical improvement within a week in responding patients, pointing toward capsule-based delivery as a practical route worth developing further. For now, the meta-analysis positions FMT as a promising salvage option for steroid-refractory gastrointestinal aGVHD, while underscoring that rigorous prospective trials with standardized donor screening, delivery protocols, and long-term follow-up are needed before it can be considered standard of care.

Evidence rating

EMERGING — 84/100

Caveats:

• This meta-analysis pooled only 6 studies and 262 patients total — the treatment findings are promising but the evidence base is small and further replication is needed.
• Four of the six included studies were conducted in China, limiting geographic and ethnic generalizability.
• FMT from allogeneic donors was associated with a higher risk of aGVHD onset compared to conventional regimens; autologous FMT did not carry this signal, suggesting donor source matters.
• Funding was not disclosed by the authors.

Systematic review and meta-analysis of 3 RCTs and 3 cohort studies (n=262). Demonstrates a significant association between FMT and improved complete response rates in gastrointestinal aGVHD, but cannot establish causation with certainty given the small aggregate sample and methodological heterogeneity across studies. Findings are consistent with prior mechanistic data but have not yet been replicated in a single large-scale independent trial.